GE HealthCare Q1 revenue up 7.4% but net income drops; cuts full-year guidance on inflation and tariffs

GE HealthCare Technologies Inc.

2026-Q1 EPS reported $0.85 vs consensus $1.07 ▼ miss (-20.6%)

Revenue $5.1B (+7.4% reported, +2.9% organic); net income $389M vs $564M; diluted EPS $0.85 vs $1.23; adjusted EPS $0.99 vs $1.01.
Adjusted EBIT margin 13.5% vs 15.0%, down 150 bps; FY guidance reduced to 15.4-15.7% (from 15.8-16.1%).
FY 2026 Adjusted EPS guidance cut to $4.80-$5.00 (from $4.95-$5.15); Free cash flow guides ~$1.6B (from ~$1.7B).
PDx supplier issue (now resolved), memory chip/oil/freight inflation, and tariffs hurt margins; no IEEPA tariff refund assumed.
Closed Intelerad acquisition for $2.3B; repurchased $100M in shares (1.4M shares) during quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

GE HealthCare Technologies Inc. updated its first quarter ended March 31, 2026 guidance (reaffirmed).

Period: first quarter ended March 31, 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On April 29, 2026 , GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its first quarter 2026 financial results.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

GE HealthCare Technologies Inc. filing history →

Source: SEC EDGAR

accession 0001932393-26-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.